STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

NCT00088101 | Completed Phase 1

• 1 other identifier: 5312-01
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 8

Brief Summary

The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.

Conditions

Hematological Malignancies; Leukemia; Lymphoma; Metastatic or Unresectable Solid Tumors

Keywords

Hematological Malignancies; Leukemia; Lymphoma; Metastatic; Unresectable solid tumors

Interventions

STA-5312 DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female patients 18 years or older with one of the following malignancies:
• Histologically or cytologically confirmed hematological malignancy (other than Acute Myeloid Leukemia and Myelodysplastic Syndrome) and if treatment is medically indicated, or,
• Histologically-confirmed non-hematological malignancy that is metastatic or unresectable and for which no standard therapy is available.
• Patients with CLL, PLL, CML, CTCL, ATL, and Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g. chlorambucil and cyclophosphamide), anthracycline combinations \[e.g. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)\], and/or purine analogues (e.g. fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens
• Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria \[low-risk, intermediate-risk and high risk\]. All patients in the high-risk group (Stage III and IV) are eligible. Intermediate risk patients (Stage I and II) with one or more criteria of active disease (such as progressive lymphocytosis, lymphadenopathy, and splenomegaly, weight loss \> 10% within 6 months, extreme fatigue, fever and/or night sweats without evidence of infection, etc.) are also eligible
• ECOG Performance Status of 0-2
• Life expectancy of greater than 12 weeks.
• Patients must have acceptable organ and marrow function at screening and pre-dose visits as defined below unless approved medically by the clinical investigator.
• Absolute neutrophils count greater than 1,000 cells/ul for patients with hematologic malignancies and ≥1,500 cells/ul for patients with solid tumors
• Platelets greater than 100,000/ul
• Hgb greater than 8.5 g/dL
• Total bilirubin must be \<1.5 mg/dL or \< 2X upper limit of normal
• AST (SGOT) \< 2.5 times the upper limit of normal
• ALT (SGPT) \< 2.5 times the upper limit of normal
• Adequate renal function (serum creatinine \< 2.0 mg/dL or a calculated creatinine clearance greater than 50 mL/min)

You may not qualify if:

• Women who are pregnant or lactating.
• Patients who have had chemotherapy, radiotherapy (except palliative radiation delivered to \< 20% of bone marrow), immunotherapy, or corticosteroids ( \> 10 mg/day of prednisone or equivalent) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• The use of nitrosoureas or mitomycin C within 6 weeks prior to study entry.
• Patients with prior peripheral blood stem cell rescue or bone marrow transplantation.
• History of primary brain tumors or active brain metastases. (Patients with previously treated brain metastases who are not receiving corticosteroids or anticonvulsants may be considered for enrollment)
• History of stroke or other significant neurologic limitations within 6 months prior to study enrollment
• Use of any investigational agents within 4 weeks of study enrollment.
• History of severe allergic reactions to excipients (e.g. Tween 80) or had hypersensitivity reactions to other chemotherapeutic agents similar in structure to STA-5312.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
• History of active CNS-lymphoma, AIDS-related lymphoma, or any uncontrolled severe medical illness or infection.
• Grade 2 or higher sensory or motor neuropathy at screening.
• Major surgery (excluding that for diagnosis) within 4 weeks of enrollment.

Sponsors & Collaborators

• Synta Pharmaceuticals Corp.: lead

Study Sites (8)

Wilshire Oncology Medical Group

Pomona, California, 91767, United States

Location

Baptist Cancer Institute

Jacksonville, Florida, 32207, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

Tufts New England Medical Center

Boston, Massachusetts, 02111, United States

Location

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Location

Carolinas HealthCare System

Charlotte, North Carolina, 28203, United States

Location

The West Clinic

Memphis, Tennessee, 38120, United States

Location

The Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States

Location

MeSH Terms

Conditions

Hematologic Neoplasms; Leukemia; Lymphoma; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: July 20, 2004
• First Posted: July 21, 2004
• Study Start: February 1, 2004
• Study Completion: December 1, 2004
• Last Updated: December 4, 2008

Record last verified: 2008-12

Locations

US (8)